JP2006501202A5 - - Google Patents

Download PDF

Info

Publication number
JP2006501202A5
JP2006501202A5 JP2004523753A JP2004523753A JP2006501202A5 JP 2006501202 A5 JP2006501202 A5 JP 2006501202A5 JP 2004523753 A JP2004523753 A JP 2004523753A JP 2004523753 A JP2004523753 A JP 2004523753A JP 2006501202 A5 JP2006501202 A5 JP 2006501202A5
Authority
JP
Japan
Prior art keywords
alkyl
aryl
independently
group
alkylene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2004523753A
Other languages
English (en)
Japanese (ja)
Other versions
JP4568113B2 (ja
JP2006501202A (ja
Filing date
Publication date
Priority claimed from DE10233817A external-priority patent/DE10233817A1/de
Application filed filed Critical
Publication of JP2006501202A publication Critical patent/JP2006501202A/ja
Publication of JP2006501202A5 publication Critical patent/JP2006501202A5/ja
Application granted granted Critical
Publication of JP4568113B2 publication Critical patent/JP4568113B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2004523753A 2002-07-25 2003-07-18 Mch調節作用を有するジアリール置換環状尿素誘導体 Expired - Fee Related JP4568113B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10233817A DE10233817A1 (de) 2002-07-25 2002-07-25 Substituierte Diarylheterocyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
PCT/EP2003/007891 WO2004011438A1 (de) 2002-07-25 2003-07-18 Diarylsubstituierte cyclische harnstoffderivate mit mch-modulatorischer wirkung

Publications (3)

Publication Number Publication Date
JP2006501202A JP2006501202A (ja) 2006-01-12
JP2006501202A5 true JP2006501202A5 (2) 2006-08-31
JP4568113B2 JP4568113B2 (ja) 2010-10-27

Family

ID=30128364

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004523753A Expired - Fee Related JP4568113B2 (ja) 2002-07-25 2003-07-18 Mch調節作用を有するジアリール置換環状尿素誘導体

Country Status (14)

Country Link
EP (1) EP1551810B1 (2)
JP (1) JP4568113B2 (2)
AR (1) AR040514A1 (2)
AT (1) ATE535513T1 (2)
AU (2) AU2003257465A1 (2)
BR (1) BR0312916A (2)
CA (1) CA2493924A1 (2)
DE (1) DE10233817A1 (2)
IL (1) IL166471A (2)
MX (1) MXPA05001048A (2)
MY (1) MY142551A (2)
PE (1) PE20040702A1 (2)
TW (1) TW200408627A (2)
WO (2) WO2004012648A2 (2)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7241787B2 (en) 2004-01-25 2007-07-10 Sanofi-Aventis Deutschland Gmbh Substituted N-cycloexylimidazolinones, process for their preparation and their use as medicaments
DE102004003811A1 (de) * 2004-01-25 2005-08-11 Aventis Pharma Deutschland Gmbh Substituierte N-Cyclohexylimidazolinone, Verfahren ihrer Herstellung und ihre Verwendung als Arzneimittel
WO2005094817A1 (en) * 2004-03-23 2005-10-13 The Regents Of The University Of California Melanin-concentrating hormone receptor antagonists and methods of use
WO2006015279A1 (en) * 2004-07-28 2006-02-09 Neurogen Corporation Heterocyclic diamine compounds as ligands of the melanin concentrating hormone receptor useful for the treatment of obesity, diabetes, eating and sexual disorders
EP1634598A1 (en) * 2004-09-07 2006-03-15 Laboratorios Del Dr. Esteve, S.A. Use of piperazine derivatives and analogues for the manufacture of a medicament for the prophylaxis and/or treatment of disorders of food ingestion
JP5250967B2 (ja) * 2005-11-30 2013-07-31 三菱化学株式会社 有機化合物、電荷輸送材料、電荷輸送材料用組成物および有機電界発光素子
CN101287713A (zh) 2005-11-30 2008-10-15 三菱化学株式会社 有机化合物、电荷传输材料、电荷传输材料用组合物和有机电致发光元件
CA2626220A1 (en) 2005-12-21 2007-06-28 Janssen Pharmaceutica N.V. Novel substituted pyrazinone derivatives for use in mch-1 mediated diseases
WO2007093365A2 (en) * 2006-02-15 2007-08-23 Sanofi-Aventis Novel amino alcohol-substituted arylthienopyrimidinones, process for their preparation and their use as medicaments
EP2061767B1 (de) 2006-08-08 2014-12-17 Sanofi Arylaminoaryl-alkyl-substituierte Imidazolidin-2,4-dione, Verfahren zu ihrer Herstellung, diese Verbindungen enthaltende Arzneimittel und ihre Verwendung
EP2102208B1 (en) 2006-12-05 2014-04-23 Janssen Pharmaceutica NV Novel substituted diaza spiro pyridinone derivatives for use in mch-1 mediated diseases
UY31968A (es) 2008-07-09 2010-01-29 Sanofi Aventis Nuevos derivados heterocíclicos, sus procesos para su preparación, y sus usos terapéuticos
DE102008049675A1 (de) 2008-09-30 2010-04-01 Markus Dr. Heinrich Verfahren zur Herstellung von 3-Aminobiphenylen
EP2348857B1 (en) 2008-10-22 2016-02-24 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
US8329914B2 (en) 2008-10-31 2012-12-11 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
KR20120060207A (ko) 2009-08-26 2012-06-11 사노피 신규한 결정성 헤테로방향족 플루오로글리코시드 수화물, 이들 화합물을 포함하는 약제 및 이들의 용도
JP2013520502A (ja) 2010-02-25 2013-06-06 メルク・シャープ・エンド・ドーム・コーポレイション 有用な抗糖尿病薬である新規な環状ベンズイミダゾール誘導体
SG192941A1 (en) 2011-02-25 2013-09-30 Merck Sharp & Dohme Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
EP2766349B1 (de) 2011-03-08 2016-06-01 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012120058A1 (de) 2011-03-08 2012-09-13 Sanofi Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683699B1 (de) 2011-03-08 2015-06-24 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8828994B2 (en) 2011-03-08 2014-09-09 Sanofi Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8895547B2 (en) 2011-03-08 2014-11-25 Sanofi Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
EP2683704B1 (de) 2011-03-08 2014-12-17 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120056A1 (de) 2011-03-08 2012-09-13 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683702B1 (de) 2011-03-08 2014-12-24 Sanofi Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012120051A1 (de) 2011-03-08 2012-09-13 Sanofi Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
RU2465895C1 (ru) * 2011-09-08 2012-11-10 Государственное образовательное учреждение высшего профессионального образования "Мордовский государственный университет им. Н.П. Огарева" Способ лечения депрессивного невроза
RU2015106909A (ru) 2012-08-02 2016-09-27 Мерк Шарп И Доум Корп. Антидиабетические трициклические соединения
KR20150118158A (ko) 2013-02-22 2015-10-21 머크 샤프 앤드 돔 코포레이션 항당뇨병 비시클릭 화합물
WO2014139388A1 (en) 2013-03-14 2014-09-18 Merck Sharp & Dohme Corp. Novel indole derivatives useful as anti-diabetic agents
CN105473558B (zh) 2013-06-20 2019-04-19 拜耳作物科学股份公司 作为杀螨剂和杀昆虫剂的芳基硫化物衍生物和芳基硫氧化物衍生物
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
WO2016100940A1 (en) 2014-12-19 2016-06-23 The Broad Institute, Inc. Dopamine d2 receptor ligands
US10752588B2 (en) 2014-12-19 2020-08-25 The Broad Institute, Inc. Dopamine D2 receptor ligands
US11072602B2 (en) 2016-12-06 2021-07-27 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
EP3558298B1 (en) 2016-12-20 2026-03-11 Merck Sharp & Dohme LLC Antidiabetic spirochroman compounds
WO2020140054A1 (en) 2018-12-28 2020-07-02 Spv Therapeutics Inc. Cyclin-dependent kinase inhibitors

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0002649A3 (en) * 1977-12-19 1979-07-11 Sandoz Ag 1-dimethyl-substituted alkyl-2- or 4-substituted phenylimidazoles, their production and their use as anti-obesity agents
DE4107857A1 (de) * 1991-03-12 1992-09-17 Thomae Gmbh Dr K Cyclische harnstoffderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
WO1996025410A1 (en) * 1995-02-17 1996-08-22 Takeda Chemical Industries, Ltd. Azole compounds, their production and use
FR2764889B1 (fr) * 1997-06-20 2000-09-01 Sod Conseils Rech Applic Nouveaux derives du 2-(iminomethyl)amino-phenyle, leur preparation, leur application a titre de medicaments et les compositions pharmaceutiques les contenant
US6096745A (en) * 1998-03-25 2000-08-01 Bristol-Myers Squibb Co. Imidazolone anorectic agents: III. heteroaryl derivatives
JP2002003370A (ja) * 1999-09-20 2002-01-09 Takeda Chem Ind Ltd メラニン凝集ホルモン拮抗剤
JP2004516239A (ja) * 2000-07-06 2004-06-03 ニューロジェン コーポレイション メラニン凝集ホルモン受容体リガンド
BR0112856A (pt) * 2000-07-31 2003-07-01 Smithkline Beecham Plc Método para o tratamento dos distúrbios, composto ou um sal ou solvato deste, processo para a preparação dos mesmos, composição farmacêutico, método de tratamento e/ou profilaxia de um ou mais dos distúrbios, uso de um composto, e, método para o tratamento de diabetes, grande depressão, depressão manìaca, ansiedade, esquizofrenia e distúrbios do sono, em mamìferos humanos e não humanos
GT200100147A (es) * 2000-07-31 2002-06-25 Derivados de imidazol
YU52403A (sh) * 2000-12-26 2006-03-03 Dr.Reddy's Research Foundation Heterociklična jedinjenja koja imaju antibakterijsko dejstvo, postupak za njihovo dobijanje i farmaceutske smeše koje ih sadrže
GB0200283D0 (en) * 2002-01-08 2002-02-20 Smithkline Beecham Plc Compounds

Similar Documents

Publication Publication Date Title
JP2006501202A5 (2)
JP2006517563A5 (2)
JP2021534124A5 (2)
EP1803721A4 (en) NEW GLUCITOL DERIVATIVE, PRODRUG THEREOF AND SALT AND THERAPEUTIC AGENT AGAINST DIABETES CONTAINING THIS
JP2004538259A5 (2)
AU9189301A (en) Use of substituted imidazo(1,2-A)pyridine-, imidazo(1,2-A)pyrimidine and imidazo(1,2-A)pyrazine-3-YL-amine derivatives for producing NOS-inhibiting medicaments
TW200500358A (en) Compounds
MY146279A (en) Compounds affecting glucokinase
EP1489077A4 (en) 2- FURANCARA ACID HYDRATES AND PHARMACEUTICAL COMPOSITION CONTAINING THEM
SE0102300D0 (sv) Compounds
ATE361287T1 (de) Neue indol-2-on derivate
JP2007507494A5 (2)
JP2009526794A5 (2)
BRPI0413393A (pt) fexofenadina, composição farmaceuticamente aceitável, método de tratamento antihistamìnico, composição, processo para preparar fexofenadina e uso de fexofenadina
JP2017520530A5 (2)
JP2009526792A5 (2)
ES2443342T3 (es) Combinación de inhibidor de la HMG-CoA reductasa rosuvastatina con un inhibidor de la fosfodiesterasa 4, tal como roflumilast, roflumilast-N-óxido para el tratamiento de enfermedades pulmonares inflamatorias
JP2011516511A5 (2)
KR20210008070A (ko) 신경 섬유 감작과 연관된 질환의 치료를 위한 1,3-티아졸-2-일 치환된 벤즈아미드
NO20070837L (no) Pyrido-pyrido pyrimidinderivater, fremstilling derav samt terapeutisk anvendelse for behandling av cancer.
JP2018526391A5 (2)
RU2006130000A (ru) Органические соединения
TW202003487A (zh) 經取代的2,2'—聯嘧啶基化合物、其類似物及其使用方法
RU2006130626A (ru) Замещенные циклогексилимидазолиноны с действием, модулирующим мсн
JP2015522592A5 (2)